Inhibition of Alpha Interferon (IFN-α)-Induced MicroRNA-122 Negatively Affects the Anti-Hepatitis B Virus Efficiency of IFN-α

ABSTRACT Alpha interferon (IFN-α)-based therapy can effectively treat chronic hepatitis B virus (HBV) infection, which causes life-threatening complications. Responses to IFN-α therapy vary greatly in chronic hepatitis B (CHB) patients, but underlying mechanisms are almost unknown. In this study, we found that IFN-α treatment induced a marked decrease of microRNA-122 (miR-122) expression in hepatocytes. We next showed that IFN-α-induced miR-122 downregulation was only partly due to transcriptional suppression. One IFN-stimulated gene (ISG), NT5C3, which was identified as a miR-122 target, efficiently inhibited miR-122 by binding and sequestering miR-122 with its mRNA 3′-untranslated region (3′-UTR), indicating that this ISG is involved in IFN-α-mediated miR-122 suppression. Notably, the inhibitory effect of IFN-α on miR-122 was completely abolished by blocking IFN-α-induced upregulation of NT5C3 mRNA expression by RNA interference (RNAi). Meanwhile, we observed that miR-122 dramatically inhibited HBV expression and replication. Finally, we showed that IFN-α-mediated HBV-inhibitory effects could be enhanced significantly by blocking IFN-α-induced downregulation of miR-122. We therefore concluded that IFN-α-induced inhibition of miR-122 may negatively affect the anti-HBV function of IFN-α. These data provide valuable insights for a better understanding of the antiviral mechanism of IFN-α and raise further potential interest in enhancing its anti-HBV efficacy.

[1]  L. Y. Wang,et al.  Stable expression and integrated hepatitis B virus genome in a human hepatoma cell line. , 2012, Genetics and molecular research : GMR.

[2]  G. Gao,et al.  Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G1‐modulated P53 activity , 2012, Hepatology.

[3]  K. Moore,et al.  The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. , 2011, Annual review of nutrition.

[4]  Ling Zhang,et al.  Modulation of the unfolded protein response is the core of microRNA-122-involved sensitivity to chemotherapy in hepatocellular carcinoma. , 2011, Neoplasia.

[5]  J. Ou,et al.  Effects of Interferon-α/β on HBV Replication Determined by Viral Load , 2011, PLoS pathogens.

[6]  A. Lohse,et al.  Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. , 2011, Gastroenterology.

[7]  Angela M. Liu,et al.  Two-tiered Approach Identifies a Network of Cancer and Liver Disease-related Genes Regulated by miR-122* , 2011, The Journal of Biological Chemistry.

[8]  J. Bukh,et al.  MicroRNA-122 antagonism against hepatitis C virus genotypes 1–6 and reduced efficacy by host RNA insertion or mutations in the HCV 5′ UTR , 2011, Proceedings of the National Academy of Sciences.

[9]  Jiming Zhang,et al.  Indoleamine 2,3-Dioxygenase Mediates the Antiviral Effect of Gamma Interferon against Hepatitis B Virus in Human Hepatocyte-Derived Cells , 2010, Journal of Virology.

[10]  Phillip A Sharp,et al.  MicroRNA sponges: progress and possibilities. , 2010, RNA.

[11]  Shi‐Mei Zhuang,et al.  A novel GSK‐3 beta–C/EBP alpha–miR‐122–insulin‐like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma , 2010, Hepatology.

[12]  X. Ye,et al.  Rnai-mediated Downregulation of Upar Synergizes with Targeting of Her2 through the Erk Pathway in Breast Cancer Cells , 2022 .

[13]  Hui Zhou,et al.  Liver‐enriched transcription factors regulate MicroRNA‐122 that targets CUTL1 during liver development , 2010, Hepatology.

[14]  C. Boucher,et al.  Prediction of sustained response to peginterferon alfa‐2b for hepatitis B e antigen–positive chronic hepatitis B using on‐treatment hepatitis B surface antigen decline , 2010, Hepatology.

[15]  T. Liang,et al.  Differential transcriptional responses to interferon-alpha and interferon-gamma in primary human hepatocytes. , 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[16]  Lipeng Qiu,et al.  miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. , 2010, Biochemical and biophysical research communications.

[17]  Jinhong Chang,et al.  Interferons Accelerate Decay of Replication-Competent Nucleocapsids of Hepatitis B Virus , 2010, Journal of Virology.

[18]  M. Buendia,et al.  Mechanisms of HBV-related hepatocarcinogenesis. , 2010, Journal of hepatology.

[19]  B. Cullen,et al.  MicroRNA Antagonism of the Picornaviral Life Cycle: Alternative Mechanisms of Interference , 2010, PLoS pathogens.

[20]  S. Kauppinen,et al.  Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection , 2010, Science.

[21]  E. Steyerberg,et al.  Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. , 2009, Gastroenterology.

[22]  K. Norman,et al.  Modulation of Hepatitis C Virus RNA Abundance and the Isoprenoid Biosynthesis Pathway by MicroRNA miR-122 Involves Distinct Mechanisms , 2009, Journal of Virology.

[23]  Krishna R. Kalari,et al.  Cytosolic 5′-nucleotidase III (NT5C3): gene sequence variation and functional genomics , 2009, Pharmacogenetics and genomics.

[24]  Lian-san Zhao,et al.  Clinical significance of 4 patients with chronic hepatitis B achieving HBsAg clearance by treated with pegylated interferon alpha-2a for less than 1 year: a short report , 2009, Virology Journal.

[25]  Charles E. Vejnar,et al.  Integration of microRNA miR-122 in hepatic circadian gene expression. , 2009, Genes & development.

[26]  M. Torbenson,et al.  Methylation regulates hepatitis B viral protein expression. , 2009, The Journal of infectious diseases.

[27]  T. Asselah,et al.  Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients , 2009, Hepatology.

[28]  Lai Wei,et al.  Role of ISGF3 in modulating the anti‐hepatitis B virus activity of interferon‐alpha in vitro , 2008, Journal of gastroenterology and hepatology.

[29]  Dong-er Zhang,et al.  The Level of Hepatitis B Virus Replication Is Not Affected by Protein ISG15 Modification but Is Reduced by Inhibition of UBP43 (USP18) Expression1 , 2008, The Journal of Immunology.

[30]  Bryan R. G. Williams,et al.  Interferon-inducible antiviral effectors , 2008, Nature Reviews Immunology.

[31]  H. Janssen,et al.  ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[32]  D. Trono,et al.  APOBEC3-Independent Interferon-Induced Viral Clearance in Hepatitis B Virus Transgenic Mice , 2008, Journal of Virology.

[33]  A. Munnich,et al.  miR-122, a paradigm for the role of microRNAs in the liver. , 2008, Journal of hepatology.

[34]  Y. Okamoto,et al.  Identification of molecular targets in head and neck squamous cell carcinomas based on genome-wide gene expression profiling. , 2007, Oncology reports.

[35]  Xiaonan Zhang,et al.  Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. , 2007, The Journal of general virology.

[36]  A. Kiss,et al.  Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[37]  Stefano Volinia,et al.  Interferon modulation of cellular microRNAs as an antiviral mechanism , 2007, Nature.

[38]  H. Bonkovsky,et al.  Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. , 2007, Gastroenterology.

[39]  Margaret S. Ebert,et al.  MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells , 2007, Nature Methods.

[40]  D. Trono,et al.  Induction of Antiviral Cytidine Deaminases Does Not Explain the Inhibition of Hepatitis B Virus Replication by Interferons , 2007, Journal of Virology.

[41]  C. Croce,et al.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. , 2007, Cancer research.

[42]  N. Paran,et al.  PGC-1α controls hepatitis B virus through nutritional signals , 2006, Proceedings of the National Academy of Sciences.

[43]  Rongzhen Xu,et al.  STAT1-Independent Cell Type-Specific Regulation of Antiviral APOBEC3G by IFN-α1 , 2006, The Journal of Immunology.

[44]  S. Wain-Hobson,et al.  Interferon‐inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication , 2006, Hepatology.

[45]  R. Schinazi,et al.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. , 2001, The Journal of clinical investigation.

[46]  H. Tang,et al.  Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  R. Kawaguchi,et al.  Quantitation of Hepatitis B Virus Genomic DNA by Real-Time Detection PCR , 1999, Journal of Clinical Microbiology.

[48]  W. Filipowicz,et al.  The liver-specific microRNA miR-122: biology and therapeutic potential. , 2011, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[49]  W. Filipowicz,et al.  Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy , 2009, Nature Medicine.

[50]  N. Paran,et al.  PGC-1alpha controls hepatitis B virus through nutritional signals. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Shiau,et al.  Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.